MYD88 and diffuse large B-cell lymphoma: For this, we selected a diffuse large B cell lymphoma (DLBCL) cell line, HBL1, which carries a myeloid differentiation primary response 88 (MYD88) mutation and which is sensitive to ibrutinib (Wilson et al., 2015).